MediWound Ltd. (MDWD) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MediWound Ltd. (MDWD) trades at $13.21 with AI Score 45/100 (Grade C). MediWound Ltd. is a biopharmaceutical company specializing in tissue repair and regeneration. Market cap: $170M, Sector: Healthcare.
Price as of Aug 22, 2026 · Last analyzed: May 10, 2026MDWD stock analysis for 2026: Analysts have set a consensus price target of $27.00 for MediWound Ltd., suggesting 104.4% upside from the current price of $13.21. The AI MoonshotScore is 45/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
MDWD: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
MediWound Ltd. (MDWD) Healthcare & Pipeline Overview
MediWound Ltd. is a biopharmaceutical company focused on developing and commercializing bio-therapeutic solutions for tissue repair and regeneration, primarily addressing burn care with its lead product NexoBrid, while expanding its pipeline to treat chronic wounds and other dermatological conditions, operating within the competitive biotechnology sector.
What Is the Investment Thesis for MDWD?
MediWound Ltd. presents a focused investment opportunity within the biotechnology sector, driven by its lead product NexoBrid and its pipeline of wound care solutions. The company's potential lies in the continued adoption of NexoBrid in burn treatment, offering a non-surgical alternative for eschar removal. Key growth catalysts include the advancement of EscharEx through clinical trials and its potential commercialization for chronic wound debridement. However, the company's negative profit margin of -140.8% highlights the need for improved financial performance and efficient commercialization strategies. The success of MW005 in treating basal cell carcinoma could further diversify MediWound's product portfolio. Investors should closely monitor the company's ability to achieve profitability, manage its operating expenses, and successfully navigate the regulatory landscape for its pipeline products.
Based on FMP financials and quantitative analysis
MDWD Key Highlights
Market capitalization of $170M, reflecting the company's current valuation in the biotechnology market.
- Gross margin of 19.2%, indicating the profitability of MediWound's products before operating expenses.
- Profit margin of -140.8%, highlighting the company's current challenges in achieving profitability.
- Beta of 0.15, suggesting lower volatility compared to the overall market.
- Focus on innovative bio-therapeutic solutions for tissue repair and regeneration, positioning the company in a specialized segment of the healthcare industry.
Who Are MDWD's Competitors?
MDWD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals, Inc. | $837.21 | +1.28% | $86.3B | 90 |
| VRTX Vertex Pharmaceuticals Incorporated | $548.05 | +1.44% | $139B | 98 |
| AMGN Amgen Inc. | $439.33 | +1.29% | $237B | 86 |
| ORMP Oramed Pharmaceuticals Inc. | $4.81 | +0.42% | $197M | 77 |
| CGEN Compugen Ltd. | $2.62 | -1.32% | $247M | 76 |
| NAGE Niagen Bioscience Inc | $3.21 | +1.90% | $256M | 74 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ICCC ImmuCell Corporation | $10.06 | -0.30% | $91.0M | 78 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MDWD's Key Strengths?
Innovative bio-therapeutic solutions for tissue repair and regeneration.
- Established market presence with NexoBrid for burn treatment.
- Pipeline of products in development for chronic wounds and basal cell carcinoma.
- Experienced management team with expertise in biotechnology and wound care.
What Are MDWD's Weaknesses?
Negative profit margin, indicating financial challenges.
- Reliance on a limited number of products for revenue generation.
- High research and development expenses.
- Limited commercial infrastructure compared to larger pharmaceutical companies.
What Could Drive MDWD Stock Higher?
MDWD catalyst: Results from Phase III clinical trials for EscharEx in chronic wound debridement could drive investor interest.
- Continued expansion of NexoBrid sales in existing and new markets.
- Regulatory approvals for MW005 in the treatment of low-risk basal cell carcinoma.
What Are the Key Risks for MDWD?
Financial-distress signal — its Altman Z-Score of -1.36 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-67.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for pipeline products.
- Competition from established pharmaceutical companies in the wound care market.
- Product liability claims related to NexoBrid or other products.
- Dependence on key suppliers for manufacturing and distribution.
What Are the Growth Opportunities for MDWD?
- Expansion of NexoBrid Market Share: NexoBrid, MediWound's lead product, has the potential to capture a larger share of the burn treatment market. The global burn care market is projected to reach $3.2 billion by 2027, driven by the increasing incidence of burn injuries and the demand for advanced wound care solutions. By increasing awareness and adoption of NexoBrid in burn centers and hospitals, MediWound can drive revenue growth and establish itself as a leader in burn care. Timeline: Ongoing.
- Advancement of EscharEx for Chronic Wound Debridement: EscharEx, currently in Phase II clinical trials, represents a significant growth opportunity for MediWound. The chronic wound care market is estimated to reach $12.5 billion by 2028, fueled by the rising prevalence of diabetes and other chronic conditions. Successful completion of clinical trials and subsequent commercialization of EscharEx could provide MediWound with a valuable product for addressing the unmet needs in chronic wound care. Timeline: 2-3 years.
- Development of MW005 for Basal Cell Carcinoma: MW005, in Phase I/II clinical trials, targets low-risk basal cell carcinoma, the most common form of skin cancer. The global basal cell carcinoma market is projected to reach $9.8 billion by 2030, driven by the increasing incidence of skin cancer and the demand for non-invasive treatment options. Successful development and commercialization of MW005 could diversify MediWound's product portfolio and expand its presence in the dermatology market. Timeline: 3-5 years.
- Geographic Expansion: MediWound has the opportunity to expand its geographic reach by entering new markets and regions. The global wound care market is growing rapidly in emerging economies, driven by increasing healthcare spending and improving access to healthcare services. By strategically expanding its commercial operations to new markets, MediWound can tap into new revenue streams and diversify its geographic risk. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: MediWound can leverage strategic partnerships and collaborations to accelerate its growth and expand its capabilities. Collaborating with other pharmaceutical companies, research institutions, or healthcare providers can provide access to new technologies, expertise, and resources. These partnerships can help MediWound to develop new products, expand its market reach, and strengthen its competitive position in the biotechnology industry. Timeline: Ongoing.
What Threats Does MDWD Face?
- Competition from established pharmaceutical companies and biotechnology firms.
- Regulatory hurdles and clinical trial risks.
- Pricing pressures and reimbursement challenges.
- Product liability risks.
What Are MDWD's Competitive Advantages?
- Proprietary bio-therapeutic technology.
- Established market presence with NexoBrid.
- Pipeline of innovative products in development.
- Specialized expertise in wound care and dermatology.
What Does MDWD Do?
Founded in 2000 and headquartered in Yavne, Israel, MediWound Ltd. is a biopharmaceutical company dedicated to developing, manufacturing, and commercializing innovative bio-therapeutic solutions for tissue repair and regeneration. The company's flagship product, NexoBrid, is a biopharmaceutical product designed for the removal of eschar, which is dead or damaged tissue, in adult patients with deep partial- and full-thickness thermal burns. NexoBrid is marketed to burn centers and hospital burn units, offering a non-surgical alternative for eschar removal. Beyond NexoBrid, MediWound is actively developing EscharEx, a product that has completed Phase II clinical trials, intended for the debridement of chronic and other hard-to-heal wounds. Additionally, the company is advancing MW005, currently in Phase I/II clinical trials, for the treatment of low-risk basal cell carcinoma. MediWound's focus is on addressing unmet needs in wound care and dermatological conditions through its innovative bio-therapeutic solutions, positioning itself as a key player in the biotechnology industry with a commitment to improving patient outcomes.
What Products and Services Does MDWD Offer?
- Develops bio-therapeutic solutions for tissue repair and regeneration.
- Manufactures novel products for wound care.
- Commercializes products for burn treatment and chronic wound debridement.
- Markets NexoBrid for eschar removal in burn patients.
- Conducts clinical trials for new product development.
- Focuses on addressing unmet needs in wound care and dermatology.
How Does MDWD Make Money?
- Develops and manufactures bio-therapeutic products.
- Markets and sells products directly to hospitals and burn centers.
- Generates revenue through product sales.
- Invests in research and development to expand its product pipeline.
What Industry Does MDWD Operate In?
MediWound Ltd. operates within the biotechnology industry, which is characterized by rapid innovation, intense competition, and high regulatory scrutiny. The market for wound care solutions is driven by the increasing prevalence of chronic diseases, such as diabetes and obesity, which contribute to the development of chronic wounds. The competitive landscape includes both established pharmaceutical companies and smaller biotechnology firms, all vying for market share. MediWound's focus on bio-therapeutic solutions for tissue repair and regeneration positions it within a niche segment of the industry, where innovation and clinical efficacy are key differentiators.
Who Are MDWD's Key Customers?
- Burn centers.
- Hospitals burn units.
- Healthcare providers specializing in wound care.
- Patients with deep partial- and full-thickness thermal burns.
Company Profile
MediWound Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Yavne, IL. The company is led by CEO Ofer Gonen. MDWD has traded publicly since 2014.
How MediWound Ltd. Is Valued
MediWound Ltd. carries a market capitalization of $170M, placing it in the micro-cap category. Relative to its peer group, MDWD's quantitative score of 45/100 is below the peer average of 85/100.
Key Financial Metrics
Return on equity for MediWound Ltd. stands at -67.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -32.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.41 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.7%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
MediWound Ltd.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.36 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project MediWound Ltd. revenue of about $23.7M for fiscal 2026, with EPS near $-2.19. The estimate reflects 5 contributing analysts.
MDWD Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- MediWound's NexoBrid seems to be gaining traction in the burn treatment space, with positive signals from key opinion leaders and hospitals.
- Insider buying activity over the past month suggests that those closest to the company see potential upside.
- The social trading community is buzzing about potential partnerships that could expand NexoBrid's market reach.
- There's a growing narrative that MediWound is undervalued compared to its peers in the wound care market.
Bear Case
- Competition in the burn treatment market is fierce, with established players holding significant market share.
- Community sentiment indicates some concern regarding the slow pace of regulatory approvals in certain key markets.
- Recent market volatility has created a risk-off environment, potentially impacting smaller biotech companies like MediWound.
- There are lingering questions about the long-term efficacy and cost-effectiveness of NexoBrid compared to traditional treatments.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
MDWD Latest News
No recent news available for MDWD.
MDWD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MDWD.
Price Targets
Consensus target: $27.00
MDWD MoonshotScore
What does this score mean?
The MoonshotScore rates MDWD 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Ofer Gonen
CEO
Ofer Gonen serves as the Chief Executive Officer of MediWound Ltd. His background includes extensive experience in the pharmaceutical and biotechnology industries. Prior to joining MediWound, he held leadership positions at various healthcare companies, focusing on strategic planning, business development, and commercial operations. His expertise spans across multiple therapeutic areas, including wound care, dermatology, and oncology. He is responsible for leading the company's overall strategy and execution.
Track Record: Under Ofer Gonen's leadership, MediWound has focused on expanding the market reach of NexoBrid and advancing its pipeline of innovative products. He has overseen the progress of EscharEx through clinical trials and the development of MW005 for basal cell carcinoma. His strategic decisions have aimed at driving revenue growth, improving operational efficiency, and strengthening the company's competitive position in the biotechnology industry.
Common Questions About MDWD (Healthcare)
What does the AI Score mean for MDWD?
MDWD holds an AI Score of 45/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. MediWound Ltd. is a biopharmaceutical company specializing in tissue repair and regeneration. Their primary product, NexoBrid, is used for eschar removal in burn patients.
What does MediWound Ltd. do?
MediWound Ltd. is a biopharmaceutical company that develops, manufactures, and commercializes innovative bio-therapeutic solutions for tissue repair and regeneration. Its primary product, NexoBrid, is used for the removal of eschar, or dead tissue, in adults with deep partial- and full-thickness thermal burns.
What do analysts say about MDWD stock?
Analyst coverage of MediWound Ltd. typically focuses on the company's growth prospects, driven by the commercial success of NexoBrid and the potential of its pipeline products. Key valuation metrics include revenue growth, gross margin, and profitability.
What are the main risks for MDWD?
MediWound Ltd. faces several key risks, including the potential failure to obtain regulatory approvals for its pipeline products, competition from established pharmaceutical companies in the wound care market, and product liability claims related to NexoBrid or other products. The company is also dependent on key suppliers for manufacturing and distribution, which could disrupt its supply chain.
What are the key factors to evaluate for MDWD?
MediWound Ltd. (MDWD) holds an AI score of 45/100 (low). presents a focused investment opportunity within the biotechnology sector, driven by its lead product NexoBrid and its pipeline of wound care solutions. Not financial advice.
How frequently does MDWD data refresh on this page?
MDWD's price was last updated on Aug 22, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MDWD's recent stock price performance?
MediWound Ltd. (MDWD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative bio-therapeutic solutions for tissue repair and regeneration. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MDWD overvalued or undervalued right now?
MediWound Ltd. (MDWD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MDWD before investing?
Before investing in MediWound Ltd. (MDWD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data may be outdated.
- Analyst opinions may vary.